These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37353178)

  • 1. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
    Crocetto F; Ferro M; Buonerba C; Bardi L; Dolce P; Scafuri L; Mirto BF; Verde A; Sciarra A; Barone B; Calogero A; Sagnelli C; Busetto GM; Del Giudice F; Cilio S; Sonpavde G; Di Trolio R; Della Ratta GL; Barbato G; Di Lorenzo G
    Crit Rev Oncol Hematol; 2023 Aug; 188():104059. PubMed ID: 37353178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
    Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
    J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
    Li C; Li Z; Sun Q; Xiang Y; Liu A
    Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
    van Dorst DCH; van Doorn L; Mirabito Colafella KM; Manintveld OC; Hassing HC; Danser AHJ; Mathijssen RHJ; Versmissen J
    Clin Sci (Lond); 2021 Jul; 135(14):1649-1668. PubMed ID: 34283204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis.
    Minegishi S; Kinguchi S; Horita N; Namkoong H; Briasoulis A; Ishigami T; Tamura K; Nishiyama A; Yano Y;
    Hypertension; 2022 Nov; 79(11):2611-2621. PubMed ID: 36093785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis.
    Li X; Li D
    Front Immunol; 2024; 15():1394123. PubMed ID: 38979409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion.
    Zhong P; He M; Yu H; Wu Q; Peng Q; Huang M; Xue Y; Yang X
    Curr Eye Res; 2020 May; 45(5):615-622. PubMed ID: 31670978
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
    Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
    Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Evans JR
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.